Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding childrens) meta-analysis

Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021
 
NCT04452318
RCTcasirivimab/imdevimab (Ronapreve)placeboCOVID-19 prophylaxis (excluding childrens)some concern
753/752 conclusif
  • demonstrated 83 % decrease in symptomatic Covid-19 (PE) with a moderate degree of certainty due to some concern in risk of bias
  • statistically significant 2.0-fold increase in serious adverse events with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).